<DOC>
	<DOCNO>NCT00544115</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor peripheral stem cell transplant help stop growth cancer abnormal cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus , methotrexate , cyclosporine , mycophenolate mofetil , sirolimus transplant may stop happen . PURPOSE : This phase II trial study well donor peripheral stem cell transplant work treat patient advanced hematologic cancer disorder .</brief_summary>
	<brief_title>Donor Peripheral Stem Cell Transplant Treating Patients With Advanced Hematologic Cancer Other Disorders</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate hematopoietic recovery , use neutrophil platelet engraftment primary criterion , patient advance hematologic malignancy disorder undergo allogeneic peripheral blood stem cell ( PBSC ) transplantation match unrelated donor . - To evaluate incidence acute chronic graft-versus-host-disease ( GVHD ) patient undergo allogeneic PBSC transplantation match unrelated donor . Secondary - To evaluate impact HLA class I class II allele-matching incidence GVHD survival outcome patient . - To evaluate overall survival , disease-free survival , relapse patient . OUTLINE : Patients stratify accord type conditioning regimen ( myeloablative v reduced-intensity myeloablative ) . Patients assign condition regimen accord diagnosis , age , disease status , prior radiotherapy , prior autologous stem cell transplantation . - Conditioning regimen : - Regimen I : Patients undergo total body irradiation ( TBI ) day -7 -4 receive cyclophosphamide IV day -3 -2 . Alternatively , patient may receive cyclophosphamide day -7 -6 undergo TBI day -4 -1 . - Regimen II : Patients receive busulfan IV 2 hour day -8 every 6 hour day -7 -4 . Patients also receive cyclophosphamide IV day -3 -2 . - Regimen III : Patients undergo TBI day -7 -4 receive etoposide IV day -3 . - Regimen IV : Patients receive fludarabine phosphate IV 30 minute day -7 -3 melphalan IV day -2 . - Regimen V : Patients receive fludarabine phosphate IV 30 minute day -4 -2 undergo TBI day 0 . - Regimen VI : Patients receive busulfan IV 3 hour fludarabine phosphate IV 30 minute day -5 -2 . - Allogeneic peripheral blood stem cell ( PBSC ) transplantation : All patient undergo allogeneic PBSC transplantation day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive one follow GVHD prophylaxis regimen : - Regimen A : Patients receive tacrolimus IV orally day -1 180 methotrexate IV day 1 , 3 , 6 , 11 . - Regimen B : Patients receive cyclosporine IV orally twice daily day -1 180 , mycophenolate mofetil IV 2 hour orally twice daily day 0-27 , methotrexate IV day 1 , 3 , 6 . - Regimen C : Patients receive tacrolimus IV continuously orally , oral sirolimus begin day -3 . Patients also receive methotrexate IV day 1 , 3 , 6 . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Acute lymphocytic leukemia ( ALL ) , meet one follow criterion : In first relapse beyond Highrisk ALL , define follow : Hypoploidy ( ≤ 44 chromosome ) Pseudodiploidy translocation molecular evidence ( 9 ; 22 ) , 11q23 , ( 8 ; 14 ) , exclude Bcell ALL Elevated WBC presentation ( WBC &gt; 20,000/mm³ [ patient &gt; 18 year age ] ; WBC &gt; 200,000/mm³ [ patient 1218 year age ] ) Acute myeloid leukemia ( AML ) , meet one follow criterion : In first complete remission Failed achieve remission In first relapse beyond Secondary AML ( &gt; 30 % blast marrow aspirate ) Should receive induction chemotherapy obtain remission , possible , transplant Chronic myelogenous leukemia , meet one follow criterion : In first second chronic phase accelerate phase In blast crisis , define &gt; 30 % promyelocytes plus blast bone marrow Myelodysplastic syndrome , include follow : Refractory anemia excess blast ( RAEB ) Chronic myelomonocytic leukemia RAEB transformation Refractory nonHodgkin lymphoma , chronic lymphocytic leukemia , Hodgkin lymphoma , multiple myeloma Received fail frontline therapy , highdose therapy autologous stem cell transplantation , salvage therapy Myeloproliferative disorders/myelofibrosis may allow case case basis Severe aplastic anemia , paroxysmal nocturnal hemoglobinuria , hematologic disorder require transplantation Patients &gt; 55 year age hematologic diseases treatable allogeneic stem cell transplantation eligible IRB 99190 eligible No uncontrolled CNS involvement disease No match ( 6/6 ) relate donor available HLAidentical unrelated donor available HLAphenotypically identical HLAA HLAB alleles identical DRB1 allele DNA type class I class II antigens Allele mismatch HLA class I ( i.e. , B 2701 v B 2702 ) allow alternative donor Allele mismatch class II ( i.e. , DRB1 0401 v 0402 ) minor mismatch class I cross reactive group ( CREG ) ( i.e. , A 2 v A 28 ) allow patient ≤ 35 year age require urgent transplant PATIENT CHARACTERISTICS : Karnofsky performance status 50100 % Life expectancy &gt; 8 week LVEF ≥ 45 % rest AST ≤ 2 time normal ( unless liver function abnormality due underlying disease ) Total bilirubin &lt; 1.5 time normal ( unless liver function abnormality due underlying disease ) Creatinine ≤ 1.5 time normal OR creatinine clearance ≥ 60 mL/min DLCO ≥ 40 % predict ( correct hemoglobin ) No coexist medical problem would significantly increase risk transplant procedure HIV negative Not pregnant PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>paroxysmal nocturnal hemoglobinuria</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II multiple myeloma</keyword>
</DOC>